CRTC1 and breast carcinoma: Most notably, BCAT overexpression has been associated with brain, urothelial, bladder, and breast cancers, for which treatment or clinical trials with the rapamycin analog everolimus have been approved or are underway, respectively, highlighting the coincidence of BCAT and TORC1 defects in human disease [79–81].